ARPA-H announced its performer teams for the THRIVE program, committing up to $160 million over five years to develop personalized, curative in vivo genetic medicines for rare diseases. The program is designed to create…
Fortress Biotech, through its subsidiary Cyprium Therapeutics, has completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the FDA approval of ZYCUBO (copper histidinate) for Menkes disease….
Novartis agreed to acquire Myricx Bio for up to $1.5 billion, including $1.1 billion upfront, to add a novel N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate payload platform and two lead ADC assets. The transaction is…
Genentech entered a breast cancer drug discovery collaboration with Astex Pharmaceuticals worth up to $490 million in milestones, while Fierce Biotech reported that 103 roles were affected as part of Genentech Research and Early…
Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients.
Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control…
RQ Bio announced the successful completion of an oversubscribed $115 million Series A financing, led by Frazier Life Sciences, to advance its long-acting antibody platform for influenza prevention. The financing will support IND-enabling development…
ADC Therapeutics announced a strategic reorganization that will reduce its workforce by approximately 17%, with resources redirected toward Zynlonta growth opportunities and regulatory priorities. The move follows safety concerns in LOTIS-5 and represents a…
SonoThera closed an oversubscribed $125M Series B financing to advance DMD and ADPKD programs toward the clinic, validating its non-viral genetic medicine delivery platform.
GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild…
